Zenas BioPharma Stock

www.zenasbio.comHealthcare / BioTech & PharmaFounded: 2020

Zenas BioPharma is a biopharmaceutical company that is striving to develop and commercialize inflammatory and immunology therapies. The company aims to address the unmet needs of patients who experience autoimmune and rare diseases by discovering differentiated approaches to current treatments. Zenas BioPharma was founded in 2019 and is headquartered in Waltham, MA. The company's lead product candidate is obexelimab, which is a bifunctional monoclonal antibody that was designed to inhibit B-cell activity.

Register To Buy and Sell Shares

For more details on financing and valuation for Zenas BioPharma, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Zenas BioPharma’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Zenas BioPharma.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Zenas BioPharma investors also invested in these private companies

Norwest Venture Partners
Pivotal bioVenture Partners
SR One Capital Management
Federated Hermes
Lepu Biopharma
Quantum Ventures
Fairmount Funds Management
Quan Capital
Superstring Capital Management
Tellus BioVentures
Wuxi Biologics

Team

Management Team

Lonnie Moulder Jr.
Founder & Chief Executive Officer
Joseph Farmer JD
President & Chief Operating Officer
Jennifer Fox
Chief Financial Officer & Chief Business Officer
Caroline Chevalier
Chief Human Resources Officer
Tanya Fischer
Chief Medical Officer & Head of Research and Development

Board Members

Hongbo Lu Ph.D
Vivo Capital
Jake Nunn
SR One Capital Management
James Boylan
Enavate Sciences
Marietta Wu Ph.D
Quan Capital
Patrick Enright
Longitude Capital

Frequently Asked Questions About Zenas BioPharma’s Stock

plusminus
Can you buy Zenas BioPharma’s stock?
Zenas BioPharma is not publicly traded on NYSE or NASDAQ in the U.S. To buy Zenas BioPharma’s stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell Zenas BioPharma’s stock?
Yes, you can sell stock of a private company like Zenas BioPharma. Forge can help you sell your Zenas BioPharma stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus
What is Zenas BioPharma’s stock price?
Zenas BioPharma is a privately held company and therefore does not have a public stock price. However, you may access Zenas BioPharma’s private market stock price with Forge Data.
plusminus
What is Zenas BioPharma’s stock ticker symbol?
Zenas BioPharma does not have an official ticker symbol because this company is not currently publicly traded.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Zenas, with new funding, aims dual-targeting antibody at lupus and MS
In a series C funding round, Zenas raised $200 million from investors.
Updated on: May 25, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.